Anzeige
Mehr »
Login
Donnerstag, 20.03.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt einsteigen, bevor der Boom beginnt: Diese bahnbrechende Technologie erobert den Markt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MU8Y | ISIN: ES0157097017 | Ticker-Symbol: E2Z
Tradegate
20.03.25
13:11 Uhr
10,360 Euro
-0,060
-0,58 %
Branche
Pharma
Aktienmarkt
IBEX MEDIUM CAP
1-Jahres-Chart
ALMIRALL SA Chart 1 Jahr
5-Tage-Chart
ALMIRALL SA 5-Tage-Chart
RealtimeGeldBriefZeit
10,24010,32023:00
10,24010,32022:00

Aktuelle News zur ALMIRALL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.03.Almirall, S.A.: Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025380CFO transition plan focusses on business continuity and the company's strong growth trajectory as European leader in medical dermatology Jon U. Garay Alonso has over 25 years of experience...
► Artikel lesen
06.03.ALMIRALL, S.A.: Almirall announces CFO leadership transition plan4
25.02.Almirall, S.A. reports FY results15
ALMIRALL Aktie jetzt für 0€ handeln
24.02.Almirall stock jumps over 6% as 2024 results beat estimates, positive 2025 outlook6
24.02.Almirall Turns To Profit In FY24; Sees Growth In FY25 Net Sales, EBITDA4
24.02.ALMIRALL, S.A.: Presentation FY2024 Financial Results5
24.02.ALMIRALL, S.A.: Webcast with analysts and institutional investors: Presentation of FY 2024 Financial Results1
24.02.Almirall, S.A.: Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline359Almirall's net sales growth in 2024 was 10.2% YoY (total of €985.7 MM) with EBITDA growth of 10.6% YoY (total of €192.6 MM) surpassing guidance for the year with all key growth drivers delivering...
► Artikel lesen
31.01.ALMIRALL, S.A.: Almirall divests Algidol® and out-licenses Sekisan®13
15.01.JP Morgan 2025: Almirall updates strategy with focus on medical dermatology18
14.01.Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth427Almirall's unique dedication to medical dermatology and innovation combined with its commercial excellence fuel an era of sustained double-digit growth (net sales CAGR 2023-2030) and profitability...
► Artikel lesen
13.01.ALMIRALL, S.A.: Presentation: J.P. Morgan Healthcare Conference 20253
04.12.24Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare54580th anniversary commemorative events The Hive is aimed at advancing research in life sciences by a novel approach to collaboration creating an open innovation hub designed to build close...
► Artikel lesen
11.11.24Almirall, S.A. reports nine-month 2024 results; reaffirms FY24 outlook6
11.11.24Almirall, S.A.: Almirall's Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth574Positive growth trajectory maintained with Net Sales increase of 7.9% to a total of €727.6 MM, EBITDA of €142.2 MM (+2.9% YoY) driven by increased overall sales and strong performance of the...
► Artikel lesen
11.11.24ALMIRALL, S.A.: Almirall files Nine Months results presentation for 20245
11.11.24ALMIRALL, S.A.: Almirall announces that it will webcast a conference to introduce and explain the results for the first nine months of 20244
30.10.24Almirall celebrates inner circles that help patients, making friends and family its focus for psoriasis day1
15.10.24Almirall completes EU regulatory procedure for antifungal Jublia9
15.10.24Almirall, S.A.: Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe358Efinaconazole is a triazole antifungal compound indicated for the treatment of onychomycosis, a persistent and difficult to treat fungal infection of the nail The completion of the decentralized...
► Artikel lesen
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1